OncoMatch/Clinical Trials/NCT05758610
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Is NCT05758610 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ETH-155008 for nhl, adult.
Treatment: ETH-155008 — This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are ineligible for standard treatment options.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
previously treated with at least 2 prior lines of systemic therapy with at least 1 line being an anti-cluster of differentiation antigen 20(anti-CD20) antibody-containing combination regimen
Must have received: systemic therapy
prior treatment with at least 2 lines of systemic therapy, including Bruton's tyrosine kinase(BTK) inhibitors or B-cell lymphoma-2(BCL-2) inhibitors, is required
Must have received: systemic therapy
prior treatment with at least 2 lines of systemic therapy (including a combination regimen of anti-CD20 antibodies and BTK inhibitors)
Must have received: standard second-line therapy or standard first-line therapy
patients who can tolerate intensive therapy or autologous hematopoietic stem cell transplantation are required to have received standard second-line therapy in the past but have failed or relapsed. If patients cannot tolerate intensive therapy or autologous hematopoietic stem cell transplantation, they must have received standard first-line therapy in the past, but therapy failed or relapsed
Must have received: systemic standard dose of drugs
adequately treated with a systemic standard dose of drugs in the past without remission or recurrence
Cannot have received: CDK4/6 inhibitor
Prior treatment with a cyclin dependent kinase 4 and 6(CDK4/6) ... inhibitor
Cannot have received: Pim inhibitor
Prior treatment with a ... Pim inhibitor
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previously received allogeneic hematopoietic stem cell transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months prior to initial administration of ETH-155008
The patient received autologous hematopoietic stem cell transplantation (HSCT) within 3 months prior to initial administration of ETH-155008
Cannot have received: chemotherapy or targeted therapy
Exception: within 2 weeks (or five half-lives, which is the longer) prior to first dosing treatment
Prior chemotherapy or targeted therapy within 2 weeks(Or five half-lives, which is the longer) prior to first dosing treatment
Cannot have received: investigational anticancer agent or radiotherapy (including investigational vaccines)
Exception: within 4 weeks before the first administration of ETH-155008
treatment with an investigational anticancer agent or radiotherapy (including investigational vaccines) within 4 weeks before the first administration of ETH-155008
Cannot have received: CAR-T cell therapy
Exception: within 12 weeks before the first administration of ETH-155008
Prior chimeric antigen receptor T-Cell(CAR-T) immunotherapy within 12 weeks before the first administration of ETH-155008
Lab requirements
Blood counts
For NHL: Hemoglobin ≥80g/L (≥60g/L if bone marrow invasion); Platelet count ≥75×10^9/L (≥50×10^9/L if bone marrow invasion); ANC ≥1.0×10^9/L (≥0.75×10^9/L if bone marrow invasion). For AML: WBC <25×10^9/L before first administration
Kidney function
Creatinine clearance rate(CCr)≥45 ml/min (Cockcroft-Gault formula)
Liver function
AST, ALT ≤2.5×ULN (≤5×ULN if primary liver invasion); TBIL ≤1.5×ULN (≤3×ULN if primary liver invasion)
Cardiac function
QTcF female >470ms, male >450ms excluded; no recent MI, unstable angina, significant arrhythmias, uncontrolled hypertension, stroke/TIA, VTE within 1 month, CHF NYHA III-IV, pericarditis, myocarditis, endocarditis
Blood biochemical test results must be within the following range: AST, ALT ≤2.5×ULN (≤5×ULN if primary liver invasion); TBIL ≤1.5×ULN (≤3×ULN if primary liver invasion); Creatinine clearance rate(CCr)≥45 ml/min (Cockcroft-Gault formula); Prothrombin time(PT) and activated partial thromboplastin time(aPTT) ≤1.5×ULN. For NHL, hematology laboratory parameters ... For AML, ... WBC <25×10^9/L before first administration. Cardiac: see exclusion criteria 15.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify